Company
Overview
Disease Focus
Corporate Management
Board of Directors
Corporate and social responsibility
Technology
Small Molecule Therapeutics
The Endocannabinoid System
Pipeline
Overview & Timeline
URB937
URB597
Partnerships
News
Investors
Contact
Investors
Exxel Pharma is focused on
Commercialization of its FAAH inhibitor drugs and providing innovative medicines to current, unmet medical needs.
Positioning URB937 as a novel treatment for chronic cough and a safe, non-addictive alternative to opioid drugs for pain management.
Expanding the Company’s drug pipeline with follow-on molecules, and maximizing the value of the Company’s IP portfolio.
Achieving the goal of providing optimal returns for our investors.
Exxel Pharma to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast with members of the Exxel Pharma Leadership Team on Tuesday, July 11th 1:00 PM ET
Sign-up For Investor Updates
Enter your contact information
Sign-up investors
Your Name
*
Email
*
Δ